Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (MDT) is a global leader in medical technology, developing innovative healthcare solutions that address chronic diseases and complex conditions. This dedicated news hub provides investors and professionals with timely updates on the company's strategic initiatives, regulatory milestones, and technological breakthroughs.
Access authoritative information spanning earnings announcements, product approvals, partnership developments, and clinical trial outcomes. Our curated collection ensures you stay informed about MDT's advancements in cardiac care, neuromodulation, diabetes management, and surgical robotics.
Discover press releases detailing regulatory submissions, executive appointments, and global market expansions. Each update is verified for accuracy, offering insights into how Medtronic maintains its position at the forefront of medical innovation while navigating evolving healthcare landscapes.
Bookmark this page for direct access to primary source materials and analysis-free reporting on MDT's operational developments. Regular updates ensure you never miss critical information impacting the medical technology sector.
Medtronic plc (NYSE:MDT) has received Breakthrough Device Designation from the FDA for its Emprint™ ablation catheter kit, aimed at the minimally invasive treatment of lung malignancies. This investigational device, which works with the Emprint™ microwave generator and lung navigation platform, provides localized treatment while preserving lung function. Although not yet approved in the U.S., the device is CE Marked and has completed enrollment for the NAVABLATE study in Europe and Hong Kong. The FDA's designation will facilitate priority review and support in clinical trial designs for Medtronic.
Medtronic plc (NYSE:MDT) has received FDA approval for a clinical trial evaluating its implantable tibial neuromodulation (TNM) device designed to alleviate bladder incontinence symptoms. The TITAN 1 Feasibility Study will involve 20 participants across eight U.S. sites, with enrollment starting in May 2021. Over 37 million adults in the U.S. suffer from overactive bladder, but only 5% receive advanced therapy. Medtronic aims to provide more treatment options for these patients, building on its established sacral neuromodulation therapies, to address diverse patient needs.
Medtronic (NYSE:MDT) has partnered with Surgical Theater to integrate the SyncAR™ augmented reality (AR) technology with its StealthStation™ S8 surgical navigation system. This collaboration aims to enhance visualization for neurosurgeons during complex cranial procedures. By utilizing fighter-jet simulation technology, surgeons can access real-time patient-specific information and see a 360° AR rendering overlaid on live images during surgeries. This innovation promises improved precision and efficiency in treating brain tumors and aneurysms, offering significant benefits for patient outcomes.
Medtronic has received FDA approval for its Pipeline™ Flex Embolization Device with Shield Technology, designed to enhance flow diversion therapy for brain aneurysms. The first patient procedure was performed at NYU Langone Health. This device, a market leader for a decade, reduces thrombogenicity, facilitating better delivery through complex vascular anatomy. Clinical results show a 77.2% complete aneurysm occlusion rate at 12 months, and improvements in safety and efficacy. The advancement marks a significant milestone in treating cerebral aneurysms, aiming to improve patient outcomes.
Medtronic plc (NYSE:MDT) announced 24-month results from the IN.PACT AV Access clinical study, revealing the IN.PACT™ AV drug-coated balloon (DCB) as the first DCB to demonstrate sustained effectiveness compared to standard PTA in patients with end-stage renal disease. Key findings include a target lesion primary patency of 52.2% for the DCB group versus 36.2% for PTA (p<0.001). Additionally, the study showed 39.5% access circuit primary patency for the DCB group compared to 25.4% for PTA (p<0.001). These results suggest that the IN.PACT AV DCB can reduce the need for reinterventions, enhancing patient quality of life.
Medtronic plc (NYSE: MDT) has launched the Medtronic Extended infusion set in select European countries, enabling insulin pump users to wear it for up to 7 days, which is a significant increase from the usual 3-day change requirement. This innovation reduces interruptions in therapy and enhances convenience. User feedback from over 100 participants in Finland was overwhelmingly positive, highlighting increased comfort and a reduction in infusion set failures. The product is compatible with MiniMed™ 600 and 700 series pumps and aims to simplify diabetes management.
Medtronic has received FDA clearance for the GI Genius™ module, the first AI-driven system for detecting colorectal polyps during colonoscopies. This innovative technology enhances polyp detection rates, potentially impacting over 19 million colonoscopies performed annually in the U.S. Studies indicate that using GI Genius can lead to a 14% increase in adenoma detection rates, significantly improving early cancer detection and patient outcomes. Medtronic aims to reduce colorectal cancer risks by integrating AI into gastroenterology practices, further solidifying its leadership in medical technology.
Medtronic plc (NYSE:MDT) announced its commitment to health equity for individuals of color living with diabetes, revealing plans to invest $1 million in partnerships with the American Diabetes Association and T1D Exchange over the next three years. The initiatives include the Health Equity Now project to improve access to diabetes technology and a quality improvement pilot program to enhance tech adoption among minorities. Additionally, Medtronic is supporting an NIH-funded research study focused on blood glucose management among African American youth, utilizing its advanced insulin pump technology.
Medtronic Foundation and Children's HeartLink have launched a $2.5 million partnership aimed at improving pediatric heart care in underserved regions of Brazil, India, and China. Over three years, the initiative will enhance hospital capacity, train 10,000 health workers, and provide care for 10,000 children suffering from congenital heart disease. This collaboration seeks to address health disparities and improve outcomes by utilizing both financial and human resources effectively, while honoring former Medtronic chairman Omar Ishrak's legacy.
Medtronic plc (NYSE:MDT) announced FDA approval for its Harmony™ Transcatheter Pulmonary Valve (TPV), a minimally invasive treatment for congenital heart defects affecting blood flow from the heart to the lungs. The Harmony TPV, designated as a Breakthrough Therapy, aims to replace the need for open-heart surgeries in patients with right ventricular outflow tract disruptions. Clinical data indicated excellent safety and effectiveness, with no significant reinterventions at six months. This device expands access to transcatheter technology for a broader range of congenital heart disease patients.
